Greenteaspoon

Greenteaspoon was biotechnology committed building on the promising results of a series of controlled clinical trials conducted from 2011-2018 that demonstrated promising results in individuals with symptoms of IBS-D and acute gastroenteritis. To speed the delivery of its solution(s) to those in need of relief, Greenteaspoon chose to launch the Goodgut brand of products based on their breakthrough through a direct to consumer path. By 2017 Goodgut products were available in close to 15,000 retail locations across the US. In 2020 Greenteaspoon sold the Goodgut brand.